Telemedicine Efficacy in Medication Adherence in Post-ischemic Stroke Patients

Fundación Cardiovascular de Colombia

Status: Unknown

Conditions: Compliance, Treatment; Stroke; Compliance, Patient; Compliance, Medication

Treatments: Other: in-person neurology consultation; Other: telemedicine neurology consultation

Study type: Interventional

Funder types: Other

Identifiers

NCT04877171

CEI-2020-01644

Details and patient eligibility

About

Telemedicine is an incipient resource to support the stroke system of care in Colombia. Several studies had demonstrated that patients benefit by implementing telestroke, for instance, providing timely and appropriate neurological consultation, diminishing accessible barriers, improving medication adherence for secondary prevention and facilitating linkages between patient and physician, especially for those in rural or neurologically underserved areas.

Hypothesis: The use of Telemedicine improves medication adherence in Post-ischemic Stroke.

Study Design: This is a randomized, single-blind, clinical trial to assess the efficacy of Telemedicine, over medication adherence in Post-ischemic Stroke subjects from Colombia.

Population: Eighty-four Post-ischemic Stroke subjects, subjects of both genders, over 18 years old, with a first stroke will be included.

Ethical Aspects: The study will be conducted according to the Helsinki declaration, the good clinical practices guidelines and the Colombian legislation. Prior to entering the study, patients must sign a written or oral informed consent that has been approved by the Institutional Ethics Committee of Fundación Cardiovascular de Colombia.

Overall objective: this study aims to determine the efficacy of telemedicine on pharmacological adherence in post-ischemic Stroke Participants.

Focus of study: Adherence to secondary stroke prevention medication.

Enrollment: 84 estimated patients

Sex: All

Ages: 18 to 86 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• First ischemic stroke.
• Lived in urban areas.
• Available Access to permanent internet at home, in work on mobile dispositive, computers or tablets.
• Patients who gave their written informed consent.

Exclusion criteria

• Diagnosis of neurodegenerative diseases such as dementia and Parkinson's disease.
• Diagnosis of Diseases-terminal to prevent tracking.
• Diagnosis of psychiatric illnesses such as major depressive disorder (MDD) or others.
• Global cognitive impairment or previous diagnosis of dementia.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

84 participants in 2 patient groups

telemedicine neurology consultation

Experimental group

Description:

Starting on day 12-14 post-discharge, participants will receive a phone call for a drug conciliation. Participants at 1-month post-discharge will receive a telemedicine consultation, another at 3 months and 6 months.

Treatment:

Other: telemedicine neurology consultation

in-person neurology consultation

Active Comparator group

Description:

Starting at 1-month post-discharge, participants will attend an in-person neurology consultation and the following consultations depend on their physician's criteria until completed 6 months post-discharge.

Treatment:

Other: in-person neurology consultation